Evaluation of Gastrointestinal Patient Reported Outcomes Measurement Information System (GI-PROMIS) Symptom Scales in Subjects With Inflammatory Bowel Diseases
Evaluation of Gastrointestinal Patient Reported Outcomes Measurement Information System (GI-PROMIS) Symptom Scales in Subjects With Inflammatory Bowel Diseases
复制标题
DOI：
10.1038/ajg.2017.240
复制
发表时间：
2018-01-01
影响因子：
9.8
通讯作者：
Long, Millie D.
中科院分区：
文献类型：
--
作者：
Kochar, Bharati;Martin, Christopher F.;Long, Millie D.
提示：患者报告结局（PRO）是炎症性肠病（IBD）的重要治疗终点。我们评估了胃肠道（GI）PRO测量信息系统（PROMIS）在IBD subjects.METHODS：克罗恩病和结肠炎基金会的美国合作伙伴是一个基于互联网的IBD受试者的队列。参与者完成调查，包括人口统计学，疾病特征，PROMIS领域，疾病活动（短期克罗恩病活动指数或简单临床结肠炎活动指数）和生活质量（QoL）指数。在巢式横断面研究中，我们使用单变量和双变量分析，以评估8 GI-PROMIS域（反流，吞咽，腹泻，恶心，腹痛，气体，失禁，便秘）和生活质量和疾病活动indics.RESULTS之间的关联：该研究包括2,378克罗恩病（CD）和1,455溃疡性结肠炎（UC）的受访者，中位年龄为41岁。CD受试者的中位病程为11年，UC受试者为8年; 57%的CD受试者和42%的UC受试者处于缓解状态。在有症状的CD受试者中，活动性CD受试者报告的所有8个领域的症状均显著差于缓解期受试者。在UC受试者中观察到相同的情况，但吞咽中断除外。IBD受试者生活质量较差的报告显着恶化的症状，所有8个领域相比，那些更好的QoL.CONCLUSIONS：在IBD受试者经历GI症状，GI-PROMIS域与疾病活动和生活质量指数密切相关。GI-PROMIS具有作为IBD PRO指标的潜力，并与该人群中其他经验证的指标相关。
OBJECTIVES: Patient reported outcomes (PROs) are important treatment endpoints in inflammatory bowel diseases (IBD). We evaluated the gastrointestinal (GI) PRO Measurement Information System (PROMIS) in IBD subjects.METHODS: Crohn's and Colitis Foundation of America's Partners is an Internet-based cohort of IBD subjects. Participants complete surveys, including demographics, disease characteristics, PROMIS domains, disease activity (short Crohn's disease activity index or simple clinical colitis activity index) and quality of life (QoL) indices. In a nested cross-sectional study, we used univariate and bivariate analyses to assess associations between 8 GI-PROMIS domains (reflux, swallowing, diarrhea, nausea, belly pain, gas, incontinence, and constipation) and QoL and disease activity indices.RESULTS: The study included 2,378 Crohn's Disease (CD) and 1,455 ulcerative colitis (UC) respondents with a median age of 41 years. Median disease duration was 11 years for CD subjects and 8 years for UC subjects; 57% of CD subjects and 42% of UC subjects were in remission. Among symptomatic CD subjects, those with active CD reported significantly worse symptoms on all 8 domains than those in remission. The same was observed for UC subjects with the exception of disrupted swallowing. IBD subjects with worse QoL reported significantly worse symptoms on all 8 domains compared to those with better QoL.CONCLUSIONS: In IBD subjects experiencing GI symptoms, GI-PROMIS domains were strongly associated with disease activity and QoL indices. GI-PROMIS holds potential as PRO measures in IBD and correlates with other validated indices in this population.